A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer
Sponsor: Clovis Oncology, Inc.
Listed as NCT02202746, this PHASE2 trial focuses on Breast Cancer and ER and remains terminated or withdrawn. Sponsored by Clovis Oncology, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2019 — Jul 2020 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE2
-
Oct 2018 — Aug 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clovis Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Austin, United States, Bakersfield, United States, Baltimore, United States, Boston, United States, Chicago, United States, Cleveland, United States, Dallas, United States, Deerfield Beach, United States, Fort Worth, United States, Fullerton, United States and 18 more location s